कंपनी का अवलोकन
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company dedicated to discovering and developing therapeutics specifically for neuromuscular conditions within the United States. The firm operates within the Healthcare sector and the Biotechnology industry, which implies a focus on high-risk, high-reward research and development activities aimed at addressing significant unmet medical needs. As of the latest data, the company possesses a market capitalization of $3.19B and maintains a workforce of 258 employees. The valuation figure of $3.19B indicates a substantial market presence for a clinical-stage entity, while the absence of reported annual revenue in the financial data suggests the company is likely still in the phase of capitalizing on research rather than generating commercial sales, a common characteristic for early-stage biotechnology firms.
वित्तीय स्वास्थ्य
The financial statements report a Net Income (TTM) of $-446,214,016 and an EBITDA of $-466,135,008, while Revenue (TTM) is listed as N/A. The significant negative net income relative to the near-zero revenue figure reveals a cost structure heavily weighted toward research and development expenses and operational overheads typical of drug discovery phases. The company reports a Free Cash Flow of $-260,087,008, which indicates a substantial cash burn rate that necessitates continuous financing to sustain operations and advance clinical programs. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, indicating that the company has not yet achieved profitability or generated sufficient revenue to calculate meaningful margins in the traditional sense. The balance sheet shows a Cash position of $1.11B against total Debt of $169.20M, resulting in a Debt to Equity ratio of 17.41. Despite the high debt-to-equity figure, the liquidity position appears robust given the cash reserves significantly exceed total debt obligations. The Current Ratio stands at 22.25, which indicates an extremely strong ability to meet short-term liabilities with available current assets. However, the Return on Equity is -55.7% and Return on Assets is -31.2%, revealing that management is currently destroying equity value and utilizing assets to generate losses rather than positive returns, a typical but risky profile for a pre-revenue biotechnology company.
मूल्यांकन आकलन
The Trailing P/E Ratio (TTM) is N/A due to negative earnings, while the Forward P/E is listed as -6.38, implying that expected future earnings remain negative over the next twelve months. The Price to Book ratio is 3.29, suggesting the market values the company at more than three times its net asset value, reflecting high expectations for the potential success of its drug pipeline. The Price to Sales ratio is N/A, and the EV/EBITDA is -4.83, which serves as an alternative valuation metric that highlights the company's lack of current earnings power and reliance on asset backing or future potential rather than cash flow generation. The stock has traded with a 52-Week High of $25.00 and a 52-Week Low of $6.36. Without a specific current price provided in the facts, the valuation range indicates a high degree of price volatility and sensitivity to clinical trial outcomes or market sentiment regarding neuromuscular disease therapies. The Beta is 1.28, which signifies that the stock price is expected to be 28% more volatile than the broader market, reflecting the inherent risks associated with clinical-stage biotechnology investments.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, indicating that historical growth rates cannot be calculated without prior period data. Since the company has not yet commercialized its products, earnings are not growing faster or slower than revenue in a commercial sense, as neither metric exists yet. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. This non-dividend status implies that the company reinvests all available capital and retained earnings back into research, development, and clinical trials rather than distributing cash to shareholders. Consequently, the overall growth and income profile for Dyne Therapeutics, Inc. is characterized by a focus on capital appreciation potential through asset development rather than current income generation or dividend yield, relying entirely on the successful transition of its neuromuscular disease therapeutics to the market.